Colgate-Palmolive (NYSE:CL) reported quarterly earnings of $0.79 per share which met the analyst consensus estimate. This is a 2.6 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $4.40 billion which missed the analyst consensus estimate of $4.43 billion by 0.61 percent. This is a 1.83 percent increase over sales of $4.32 billion the same period last year.
Barclays Maintains Overweight on Revance Therapeutics, Raises Price Target to $33
Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:RVNC) with a Overweight and raises the price target from $32 to $33.
